Physiology, Journal Year: 2024, Volume and Issue: 39(3), P. 128 - 128
Published: March 29, 2024
Language: Английский
Deleted Journal, Journal Year: 2025, Volume and Issue: unknown
Published: April 10, 2025
Obesity represents an immense challenge for patients and physicians due to its numerous comorbidities complications. For a long time, safe effective pharmacological treatment remained wishful thinking. Bariatric surgery was considered the only option sustained weight loss; however, with advent of incretin-based treatment, initially introduced as highly component anti-diabetic research began focus on complex gastroenteropancreatic endocrine system, including central hunger satiety regulation. This shift driven by discovery remarkable side effect: placebo-controlled reduction. Subsequent groundbreaking developments based long-acting peptides, administration which could be reduced from twice daily in earlier forms once weekly, now enables significant reduction over 20%, tolerable safety profile. article provides illustrative overview corresponding associations highlights this milestone obesity treatment.
Language: Английский
Citations
0
Molecular Metabolism, Journal Year: 2024, Volume and Issue: 83, P. 101915 - 101915
Published: March 14, 2024
The glucose-dependent insulinotropic polypeptide (GIP) decreases body weight via central GIP receptor (GIPR) signaling, but the underlying mechanisms remain largely unknown. Here, we assessed whether regulates and glucose control GIPR signaling in cells that express leptin (Lepr).
Language: Английский
Citations
3
Trends in Endocrinology and Metabolism, Journal Year: 2024, Volume and Issue: 35(7), P. 566 - 568
Published: May 18, 2024
Unimolecular co-agonists at the GLP-1/GIP receptors have recently achieved remarkable anti-obesogenic feats; yet, in a recent Phase 1 clinical trial, Véniant and colleagues report astounding body-weight loss, an appreciable safety profile, participants with obesity using GLP-1R agonist/GIPR antagonist AMG 133.
Language: Английский
Citations
3
Frontiers in Pharmacology, Journal Year: 2024, Volume and Issue: 15
Published: July 8, 2024
Aims: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are employed extensively in the management of type 2 diabetes and obesity. However, there is a paucity real-world data on their safety tolerability for metabolic nutritional adverse events large sample populations. This study aimed to analyse signatures different GLP-1 RAs by exploring Food Drug Administration (FDA) Adverse Event Reporting System (FAERS). Methods: AEs were extracted from FDA database each RA time its launch until second quarter 2023. The reported odds ratio (ROR), proportional reporting (PRR), Empirical Bayesian Geometric Mean Confidence Propagation Neural Network identify AE signals. Results: A system organ class metabolism nutrition disorders was filter reports, resulting identification 10,450 reports exenatide, 2,860 liraglutide, 240 albiglutide, 4,847 dulaglutide, 2,905 semaglutide, 1,089 tirzepatide, 13 lixisenatide. Semaglutide (ROR, 3.34; 95%CI, 3.22), liraglutide 2.78; 2.69), exenatide 2.15; 2.11) associated with disorders. number signals detected as follows: albiglutide (n = 1), lixisenatide 2), tirzepatide 11), 12), 16), semaglutide 20), dulaglutide 22). Dehydration most frequent contributing serious outcomes 318, 23.93%), 434, 20.90%), 370, 25.10%) 70, 32.86%). onset (TTO) statistically between other ( p < 0.001), Weibull parameters dehydration analyses all showed an early failure-type profile. Conclusion: Our suggests that more susceptible than RAs. Liraglutide, tirzepaptide’s potential induce dehydration, necessitates special attention. Despite certain deficiencies, have considerable treatment eating
Language: Английский
Citations
2
The Lancet Regional Health - Europe, Journal Year: 2024, Volume and Issue: 47, P. 101098 - 101098
Published: Nov. 7, 2024
Language: Английский
Citations
2
Physiology, Journal Year: 2024, Volume and Issue: 39(3), P. 128 - 128
Published: March 29, 2024
Language: Английский
Citations
0